Baak J P, van Diest P J, Ariens A T, van Beek M W, Bellot S M, Fijnheer J, van Gorp L H, Kwee W S, Los J, Peterse H C
Department of Pathology, Free University Hospital, Amsterdam, The Netherlands.
Pathol Res Pract. 1989 Nov;185(5):664-70. doi: 10.1016/S0344-0338(89)80213-4.
The Multicenter Morphometric Mammary Carcinoma Project (MMMCP) has been set up to investigate prospectively the prognostic value and reproducibility of routine assessments of the morphometric Multivariate Prognostic Index (MPI) and other quantitative parameters in comparison with classical prognosticators and steroid receptors in breast cancer patients. In this project, 34 hospitals participate, divided over six geographically different regions. Of each patient entering in the study, multiple clinical and classical pathological parameters (including tumor size and lymph node status) as well as several quantitative parameters such as mean nuclear area, DNA index and mitotic activity index will be evaluated. Of all patients, the MPI will be assessed with tumour size, lymph node status and mitotic activity index. The quantitative assessments are performed in all consecutive breast cancers which enter the participating pathology laboratories, and all measurements are controlled in Amsterdam. The patient intake time will be from January 1, 1988 until January 1, 1990. It is expected that 3000 patients will enter in this study. Follow up data will be gathered up to 10 years. However, two to five years after the initiation of the Project, a first evaluation of the reproducibility and prognostic significance of routine MPI and other assessments in breast cancer patients will be possible. A detailed description of this project is given.
多中心形态计量学乳腺癌项目(MMMCP)已启动,旨在前瞻性地研究形态计量学多变量预后指数(MPI)及其他定量参数的常规评估与乳腺癌患者的经典预后指标和类固醇受体相比的预后价值及可重复性。在该项目中,有34家医院参与,分布在六个不同的地理区域。对于每一位进入该研究的患者,将评估多个临床和经典病理参数(包括肿瘤大小和淋巴结状态)以及一些定量参数,如平均核面积、DNA指数和有丝分裂活性指数。对于所有患者,MPI将根据肿瘤大小、淋巴结状态和有丝分裂活性指数进行评估。定量评估针对所有进入参与研究的病理实验室的连续性乳腺癌病例进行,所有测量均在阿姆斯特丹进行质量控制。患者入组时间为1988年1月1日至1990年1月1日。预计将有3000名患者进入该研究。随访数据将收集长达10年。然而,在项目启动后的两到五年,将有可能对乳腺癌患者常规MPI及其他评估的可重复性和预后意义进行首次评估。本文给出了该项目的详细描述。